2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

Key Takeaways Explain This Topic AI

Contingency planning means deciding in advance, in written SOPs, what happens when HVAC, power, PECs, supplies, information systems or staff fail. It is task 1C8 of the BCSCP outline.

USP <797> requires microbiological air and surface sampling after any servicing of facilities or equipment, recertification after changes that could affect airflow, and a documented corrective action plan for out-of-range results.

If a PEC supplies part of a room's required air changes, it must not be turned off except for maintenance. Under USP <800>, work in a C-PEC stops immediately when it loses power; afterward the unit is decontaminated, cleaned and disinfected, and its recovery time is allowed before work resumes.

A 503A pharmacy may compound a copy of a drug that is on FDA's drug shortage list, because FDA does not treat a listed shortage drug as commercially available. 503B outsourcing facilities may also use shortage-list drugs.

Backup plans include qualified 503B suppliers, ready-to-use commercial products, Category 1 or immediate-use workflows while classified space is down, paper downtime procedures, and emergency power for PECs and HVAC.

Last updated: September 2026

2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

Sterile compounding depends on many systems working at once: HVAC, HEPA filters, pressure monitoring, electricity, water, sterile supplies, trained people and software. The BCSCP outline lists contingency planning (task 1C8) as its own task, because patients still need their preparations when one of those systems fails. A strong plan is written, trained, drilled and reviewed. It sets out who decides, what stops, what continues under reduced conditions, and how the facility proves it has recovered.

Failure modes and required responses

Failure Immediate action USP requirement that shapes the response

Loss of room pressure or HVAC Stop compounding; close critical sites; notify the designated person Continuous pressure monitoring with daily documented review; a documented corrective action plan for out-of-range results; microbiological sampling after servicing (USP <797> 4.2.5, 5, 6.1)

Power outage Stop work in affected PECs; protect open CSPs; move to emergency power if designed USP <800>: if a C-PEC loses power, activities stop immediately. Afterward it is decontaminated, cleaned and disinfected, and the manufacturer's recovery time passes before work resumes

PEC failure or relocation Take it out of service Recertify after replacement or relocation of any PEC, then sample air and surfaces (USP <797> 5, 6.1)

Water leak or ceiling damage Stop work; assess contamination Insanitary-conditions risk under FDA guidance; clean, disinfect and apply sporicidal; sample; repair surfaces

Failed certification or action-level excursion Restrict the affected area Corrective action plan; review follow-up data to confirm it worked (USP <797> 5.1, 6)

Storage temperature excursion Quarantine the affected CSPs The designated person decides from literature or testing whether each CSP keeps its integrity, or discards it (USP <797> 19.1)

Two USP rules often surprise candidates. First, if a PEC's HEPA-filtered air is counted toward the room's 30 air changes per hour, that PEC must not be turned off except for maintenance , because switching it off drops the room below its design. Second, servicing any facility or equipment, including a HEPA filter change, triggers microbiological air and surface sampling before normal operation resumes.

Designing a degraded-mode workflow

When the cleanroom suite is down, the question is what can still be made safely. Common, defensible options include:

Category 1 work in a certified PEC located in a segregated compounding area, if one exists, with Category 1 BUDs (12 hours at room temperature, 24 hours refrigerated).

Immediate-use preparation at the point of care for doses that truly meet all seven USP <797> 1.3 conditions (see 1.4).

Ready-to-use commercial products , such as premixed bags and prefilled syringes, which remove the need to compound.

Outsourcing to a 503B facility. The supplier should be qualified in advance: FDA registration, inspection history (Forms 483, Warning Letters), product-specific testing and dating, and a quality agreement.

Deferring non-urgent CSPs until the room is restored and sampling confirms control.

An SOP should state which option applies to which product and who authorizes the switch. Returning to normal status should require documented evidence: pressure restored, cleaning completed, sampling results reviewed and, if needed, recertification.

Supply and drug shortages

Shortages affect drugs, sterile 70% IPA, gloves, gowns, filters, growth media and syringes.

Substitution control: Any substitute supply (a different glove, filter or syringe brand) is checked for compatibility and suitability, and SOPs, MFRs and training are updated before use.

Compounding during drug shortages: For Section 503A, FDA does not consider a drug on its drug shortage list to be "commercially available." A pharmacy may therefore compound a copy of it without violating the essentially-copy restriction. Outsourcing facilities under 503B may likewise compound drugs that appear on FDA's shortage list.

Allocation and communication: The pharmacy works with prescribers and committees on therapeutic alternatives, dose rounding and conservation, and documents those decisions.

Information system downtime

IV workflow systems, ACD software, EHR order interfaces and label printers all fail sometimes. Downtime procedures should include paper compounding records that still capture every USP <797> Box 10 element, manual independent checks in place of barcode or gravimetric verification, and printed ACD recipes and calibration logs. On recovery, paper records are reconciled into the electronic system.

Staffing and competency gaps

A contingency plan must not quietly suspend personnel requirements. Anyone who compounds during an emergency still needs current garbing and aseptic manipulation competency. Cross-training more staff than the minimum schedule requires, and keeping competency dates staggered, stops qualifications from all lapsing at once.

Hazardous drug specifics (USP <800>)

A C-PEC that provides some or all of the C-SEC's negative pressure, or is used for sterile compounding, must run continuously. USP <800> suggests considering uninterruptible power for the ventilation that maintains negative pressure.

Spill kits and trained responders must be available whenever HDs are handled, including during emergencies and in non-routine locations.

Emergency power and design

ASHRAE design guidance for compounding pharmacies recommends putting PECs, room HVAC and pressure monitors on essential (backup) power circuits. A pharmacist reviewing a renovation should confirm which loads are on generator power and how long the backup lasts.

USP also published Operational Considerations for Sterile Compounding During Public Health Emergencies in October 2024. Use it as a reference when writing pandemic and disaster procedures.